Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Low pH Clear all
Completed No phase listed Observational

Influence of Acid Reflux on Stromal Epithelial Interaction in Barrett's Esophagus

NCT01281618
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
24 hour pH study and upper endoscopy (EGD)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Two-Week Study of an Anticavity Low pH Mouthwash

NCT06010758
View directory record Official record
Conditions
Healthy
Interventions
Listerine Experimental Mouthwash, Colgate Cavity Protection Toothpaste, Listerine Total Care Zero, Listerine Cool Mint Zero
Drug · Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 1 Interventional

Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

NCT01159028
View directory record Official record
Conditions
Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Ph1 Positive CML
Interventions
BP1001, BP1001 in combination with LDAC
Drug
Lead sponsor
Bio-Path Holdings, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 22, 2026, 4:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Product Characteristics on the Abuse Liability of Nicotine Pouches

NCT07165808
View directory record Official record
Conditions
Nicotine Addiction
Interventions
Nicotine pouch: Low dose, Nicotine pouch: High dose, Low pH, High pH
Other
Lead sponsor
Emory University
Other
Eligibility
21 Years to 35 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

NCT02218489
View directory record Official record
Conditions
Blepharitis
Interventions
KPI-121, Vehicle
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 22, 2026, 4:38 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

NCT03117751
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
Interventions
Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase®, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine

NCT04854746
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-GI.1.NN, Placebo Tablet
Biological
Lead sponsor
Vaxart
Industry
Eligibility
55 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Cypress, California • New Orleans, Louisiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 22, 2026, 4:38 PM EDT
Terminated Phase 2 Interventional Results available

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT03518112
View directory record Official record
Conditions
Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegfilgrastim, Rituximab, Vincristine Sulfate
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 4 Interventional Results available

Empiric Versus Selective Prevention Strategies for Kidney Stone Disease

NCT05365477
View directory record Official record
Conditions
Kidney Stones, Nephrolithiasis
Interventions
Empiric Therapy: Diet, Empiric Therapy: Drug, Selective Therapy: Diet, Selective Therapy: Drug
Behavioral · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Terminated Phase 2 Interventional Results available

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

NCT02236572
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 1Phase 2 Interventional

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

NCT04902872
View directory record Official record
Conditions
Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
Interventions
CBX-12
Drug
Lead sponsor
Cybrexa Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
New Haven, Connecticut • Austin, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 1Phase 2 Interventional

Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia

NCT00119340
View directory record Official record
Conditions
Leukemia
Interventions
cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

NCT00003239
View directory record Official record
Conditions
Leukemia
Interventions
Recombinant Interferon Alfa, Cytarabine, Omacetaxine Mepesuccinate
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 22, 2026, 4:38 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

NCT06999603
View directory record Official record
Conditions
Viral Pneumonia
Interventions
SNG001, Placebo
Drug
Lead sponsor
Synairgen Research Ltd.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Urine pH and Diet Net Acid Load

NCT02116595
View directory record Official record
Conditions
Healthy
Interventions
high or low acid diet
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual vs IV Atropine Bioavailability Study

NCT04290039
View directory record Official record
Conditions
Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions
Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 4 Interventional

Arterial pH and Total Body Nitrogen Balances in APD

NCT00586131
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
ammonium chloride or sodium citrate/citric acid, Sodium citrate/citratic acid
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 22, 2026, 4:38 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

NCT05067933
View directory record Official record
Conditions
COVID-19
Interventions
VXA-CoV2-1.1-S, Placebo Tablets
Drug · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Long Beach, California • Wichita, Kansas • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 22, 2026, 4:38 PM EDT
Recruiting Phase 1 Interventional

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

NCT05691517
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, pH Low Insertion Peptide-exatecan Conjugate CBX-12
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Not applicable Interventional

Geriatric Out of Hospital Randomized Meal Trial in Heart Failure

NCT02148679
View directory record Official record
Conditions
Heart Failure
Interventions
DASH/SRD, Usual care
Other
Lead sponsor
University of Michigan
Other
Eligibility
55 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Ann Arbor, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 22, 2026, 4:38 PM EDT
Terminated Not applicable Interventional

Acute Lung Injury Ventilator Evaluation (ALIVE)

NCT01901354
View directory record Official record
Conditions
Acute Lung Injury, Adult Respiratory Distress Syndrome
Interventions
Low-tidal-volume ventilation, Airway Pressure Release Ventilation (APRV)
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 22, 2026, 4:38 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

NCT04623996
View directory record Official record
Conditions
Anemia in Myelodysplastic Syndromes
Interventions
TP-0184
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Plantation, Florida • The Bronx, New York • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Not applicable Interventional Results available

Very Low Birth Weight Preterm Infant Bundled Care in the NICU

NCT03370757
View directory record Official record
Conditions
Preterm Infants
Interventions
3-hour bundled care, 6-hour bundled care
Other
Lead sponsor
Duke University
Other
Eligibility
Up to 32 Weeks
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 22, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma

NCT00581919
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bort, Dex, and Dox with ALCAR
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
5
States / cities
Janesville, Wisconsin • La Crosse, Wisconsin • Madison, Wisconsin + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 22, 2026, 4:38 PM EDT